Syros Pharmaceuticals, Inc.

NASDAQ:SYRS

1.95 (USD) • At close September 13, 2024
Bedrijfsnaam Syros Pharmaceuticals, Inc.
Symbool SYRS
Munteenheid USD
Prijs 1.95
Beurswaarde 52,120,185
Dividendpercentage 0%
52-weken bereik 1.43 - 8.17
Industrie Biotechnology
Sector Healthcare
CEO Dr. Nancy A. Simonian M.D.
Website https://www.syros.com

An error occurred while fetching data.

Over Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset

Vergelijkbare Aandelen

Catalyst Biosciences, Inc. logo

Catalyst Biosciences, Inc.

CBIO

0.511 USD

Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc.

CRVS

5.1 USD

Venus Concept Inc. logo

Venus Concept Inc.

VERO

0.545 USD

Accelerate Diagnostics, Inc. logo

Accelerate Diagnostics, Inc.

AXDX

1.52 USD

MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

INKT

0.776 USD

ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

1.85 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)